Reference : 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy.
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
16-kDa prolactin and bromocriptine in postpartum cardiomyopathy.
Hilfiker-Kleiner, Denise [> >]
Struman, Ingrid mailto [Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire >]
Hoch, Melanie [> >]
Podewski, Edith [> >]
Sliwa, Karen [> >]
Current Heart Failure Reports
Yes (verified by ORBi)
United States
[en] Peripartum cardiomyopathy (PPCM) is a potentially life-threatening heart disease emerging toward the end of pregnancy or in the first postpartal months in previously healthy women. Recent data suggest a central role of unbalanced peri-/postpartum oxidative stress that triggers the proteolytic cleavage of the nursing hormone prolactin (PRL) into a potent antiangiogenic, proapoptotic, and proinflammatory 16-kDa PRL fragment. This notion is supported by the observation that inhibition of PRL secretion by bromocriptine, a dopamine D2-receptor agonist, prevented the onset of disease in an animal model of PPCM and by first clinical experiences where bromocriptine seem to exert positive effects with respect to prevention or treatment of PPCM patients. Here, we highlight the current state of knowledge on diagnosis of PPCM, provide insights into the biology and pathophysiology of 16-kDa PRL and bromocriptine, and outline potential consequences for the clinical management and treatment options for PPCM patients.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Current Heart Failure PPCM 30032012.pdfAuthor preprint754.08 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.